Piper Sandler Initiates Coverage of CareDx with Overweight Rating and $100 Price Target
Piper Sandler has launched coverage on CareDx (CDNA), assigning the diagnostic product manufacturer an 'Overweight' rating. The firm set a price target of $100 per share, signaling confidence in the company's market position. Analyst David Westenberg highlighted that the Brisbane-based company is well-positioned to capitalize on significant opportunities within the solid-organ transplant sector. This initiation suggests a bullish outlook on CareDx's ability to expand its footprint in specialized diagnostic testing.
Tickers: $CDNA
Topics: analyst coverage price target stock rating
Read the full article at Seeking Alpha
Part of the story CareDx is a new Overweight at Piper Sandler on transplant testing opportunity (2 articles)